Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors

Biological Psychiatry

Volumn 45, Issue 6, 1999, Pages 668-679

  Javitt, Daniel C ^a   Balla, Andrea ^a   Sershen, Henry ^a   Lajtha, Abel ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Dopamine; Glutamate; NMDA receptors; Psychosis; Schizophrenia

Indexed keywords

GLYCINAMIDE; GLYCINE; GLYCINE TRANSPORT INHIBITOR; PHENCYCLIDINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR AFFECTING AGENT; DOPAMINE; N METHYLASPARTIC ACID; NEUROTRANSMITTER UPTAKE INHIBITOR; PSYCHEDELIC AGENT;

AMINO ACID TRANSPORT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG MECHANISM; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEGATIVE SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; AWARDS AND PRIZES; BRAIN; METABOLISM; MICRODIALYSIS; PSYCHIATRY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; AWARDS AND PRIZES; BRAIN; DOPAMINE; GLYCINE AGENTS; HALLUCINOGENS; MALE; MICRODIALYSIS; N-METHYLASPARTATE; NEUROTRANSMITTER UPTAKE INHIBITORS; PHENCYCLIDINE; PSYCHIATRY; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; TIME FACTORS;

EID: 0033558578     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00237-6     Document Type: Article

References (94)

1. Akbarian S., Sucher N.J., Bradley D., et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci. 16:1996;19-30.
2. Angrist B., Sathananthan G., Wilk S., et al. Amphetamine psychosis Behavioral and biochemical aspects . J Psychiatr Res. 11:1974;13-23.
3. Arnsten A.F., Cai J.X., Murphy B.L., Goldman-Rakic P.S. Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacol. 116:1994;143-151.
4. Bakker C.B., Amini F.B. Observations on the psychotomimetic effects of Sernyl. Compr Psychiatry. 2:1961;269-280.
5. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 271:1994;787-794.
6. Carelli R.M., Deadwyler S.A. Cellular mechanisms underlying reinforcement-related processing in the nucleus accumbens Electrophysiological studies in behaving animals . Pharmacol Biochem Behav. 57:1997;495-504.
7. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Trans. 75:1989;221-226.
8. Carpenter W.T., Buchanan R.W. Schizophrenia. N Engl J Med. 330:1994;681-694.
9. Cascella N.G., Macciardi F., Cavallini C., Smeraldi E. D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia An open-label study . J Neural Transm. 92:1994;105-111.
10. Chen G.M., Weston J.K. The analgesic and anesthetic effect of 1-(1-phenylcyclohexyl)piperidine-HCI on the monkey. Anesth Analg. 39:1960;132-137.
11. Cohen B., Rosenbaum G., Luby E.D., Gottlieb J.S. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs. Arch Gen Psychiatry. 6:1961;79-85.
12. Contreras P.C. D-serine antagonized phencyclidine-and MK-801-induced stereotyped behavior and ataxia. Neuropharmacol. 29:1990;291-293.
13. Corssen G., Domino E.F. Dissociative anesthesia Further pharmacological studies and first clinical experience with the phencyclidine derivative CL-581 . Anesth Analg. 45:1966;29-40.
14. Daniel D.G., Weinberger D.R., Jones D.W., et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 11:1991;1907-1917.
15. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 148:1991;1474-1486.
16. Debler E.A., Lajtha A. High-affinity transport of N-aminobutyric acid, glycine, taurine, L-aspartic acid, and L-glutamatic acid in synaptosomal (P2) tissue A kinetic and substrate specificity analysis . J Neurochem. 48:1987;1851-1856.
17. Deutch A.Y. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits implications for schizophrenia and Parkinson's disease . J Neural Transm. 91:1993;197-221.
18. Doherty M.D., Gratton A. NMDA receptors in nucleus accumbens modulate stress-induced dopamine release in nucleus accumbens and ventral tegmental area. Synapse. 26:1997;225-234.
19. Druhan J.P., Rajabi H., Stewart J. MK-801 increases locomotor activity without elevating extracellular dopamine levels in the nucleus accumbens. Synapse. 24:1996;135-146.
20. D'Souza D.C., Charney D., Krystal J. Glycine site agonists of the NMDA receptor A review . CNS Drug Revs. 1:1995;227-260.
21. Emmett M., Mick S., Cler J. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacol. 30:1991;1167-1171.
22. French E.D., Pilapil C., Quirion R. Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. Eur J Pharmacol. 116:1985;1-9.
23. French E.D., Vantini G. Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens Comparisons to other psychomotor stimulants . Psychopharmacol. 82:1984;83-88.
24. Furuya Y., Ogura H. Competitive NMDA and strychnine-insensitive glycine-site antagonists disrupt prepulse inhibition. Pharmacol Biochem Behav. 57:1997;909-913.
25. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
26. Goldman-Rakic P.S., Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schiz Bull. 23:1997;437-458.
27. Graybiel A.M. The basal ganglia and cognitive pattern generators. Schiz Bull. 23:1997;459-469.
28. Heresco-Levy U., Javitt D.C., et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
29. Heresco-Levy U, Javitt DC et al. (1998): Adjuvant pharmacotherapy of treatment-resistant negative and cognitive symptoms of schizophrenia with glycine, submitted for publication.
30. Hernandez L., Auerbach S., Hoebel B.G. Phencyclidine (PCP) injected in the nucleus accumbens increases extracellular dopamine and serotonin as measured by microdialysis. Life Sci. 1988;1713-1723.
31. Hirsch S.R., Das I., Garey L.J., de Belleroche J. A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction. Pharmacol Biochem Behav. 56:1997;797-802.
32. Hondo H., Yonezawa Y., Nakahara T., et al. Effect of phencyclidine on dopamine release in the rat prefrontal cortex; an in vivo microdialysis study. Brain Res. 633:1994;337-342.
33. Hood W.F., Compton R.F., Monahan J.B. D-cycloserine a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics . Neurosci Lett. 98:1989;91-95.
34. Hooks M.S., Kalivas P.W. The role of mesoaccumbens - pallidal circuitry in novelty-induced behavioral activation. Neurosci. 64:1995;587-597.
35. Javitt D.C. Negative schizophrenic symptomatology and the phencyclidine (PCP) model of schizophrenia. Hill J Psychiat. 9:1987;12-35.
36. Javitt DC, Frusciante MJ. Glycyldodecylamide (1997): Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse. Psychopharmacol 129:96-98.
37. Javitt D.C., Sershen H., Hashim A., Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake antagonist glycyldodecylamide. Neuropsychopharmacol. 17:1997;202-204.
38. Javitt D.C., Steinschneider M., Schroeder C.E., Arezzo J.C. Role of N-methyl-D-aspartate receptors in auditory sensory memory Implications for schizophrenia and drug abuse . Proc Natl Acad Sci USA. 93:1996;11962-11967.
39. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
40. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
41. Jentsch J.D., Redmond D.E. Jr, Elsworth J.D., Taylor Jr, Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
42. Johnson J.W., Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 325:1987;529-531.
43. Johnstone M., Evans V., Baigel S. Sernyl (Cl-395) in clinical anesthesia. Br J Anaesth. 31:1958;433-439.
44. Karreman M., Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum An effect mediated by ventral tegmental area . J Neurochem. 66:1996;589-598.
45. Kirkpatrick B., Carpenter W.T. Drug development and the deficit syndrome of schizophrenia. Biol Psychiatry. 38:1995;277-278.
46. Kretschmer B.D., Koch M. Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterdorsal striatum in sensorimotor gating A behavioral and microdialysis study . Psychopharmacol. 130:1997;131-138.
47. Krystal J.H., Karper L.P., Seibyl J.P., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 51:1994;199-214.
48. Kuczenski R., Segal D.S., Aizensteina M.L. Amphetamine, cocaine, and fencamfamine Relationship between locomotor and stereotype response profiles and caudate and accumbens dopamine dynamics . J Neurosci. 11:1991;2703-2712.
49. Lahti A.C., Koffel B., Laporte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacol. 13:1995;9-19.
50. Leiderman E., Zylberman I., Zukin S.R., Cooper T.B., Javitt D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia. Biol Psychiatry. 39:1996;213-215.
51. Linn G.S., O'Keeffe R.T., Schroeder C.E., Lifshitz K., Javitt D.C. Behavioral effects of chronic phencyclidine in socially-house monkeys. Soc Neurosci Abs. 23:1997;1930.
52. Liu Q.R., Lopez-Corcuera B., Mandiyan S., Nelson H., Nelson N. Cloning and expression of spinal cord- and brain-specific glycine transporter with novel structural features. J Biol Chem. 268:1993;22802-22808.
53. Loscher W., Annies R., Honack D. Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur J Pharmacol. 242:1993;263-275.
54. Luby E.D., Cohen B.D., Rosenbaum F., Gottlieb J., Kelley R. Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiat. 81:1959;363-369.
55. Luby E.D., Gottlieb J.S., Cohen B.D., Rosenbaum G., Domino E.F. Model psychoses and schizophrenia. Am J Psychiatry. 119:1962;61-67.
56. Maldonado-Irizarry C.S., Kelley A.E. Differential behavioral effects following microinjection of an NMDA antagonist into nucleus accumbens subregions. Psychopharmacol. 116:1994;65-72.
57. Malhotra A.K., Pinals D.A., Adler C.M., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacol. 17:1997;141-150.
58. Malhotra A.K., Pinals D.A., Weingartner H., et al. NMDA receptor function and human cognition The effects of ketamine in healthy volunteers . Neuropsychopharmacol. 14:1996;301-307.
59. Mansbach R.S., Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacol. 2:1989;299-308.
60. McBain C.J., Kleckner N.W., Wyrick S., Dingledine R. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Mol Pharmacol. 36:1989;556-565.
61. McCullough L.D., Salamone J.D. Increases in extracellular dopamine levels and locomotor activity after direct infusion of phencyclidine into the nucleus accumbens. Brain Res. 577:1992;1-9.
62. Moerschbaecher J.M., Thompson D.M. Effects of phencyclidine, pentobarbital, and d-amphetamine on the acquisition and performance of conditional discriminations in monkeys. Pharmacol Biochem Behav. 13:1980;887-894.
63. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex . J Neurosci. 17:1997;2921-2927.
64. Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
65. Murphy B.L., Arnsten A.F., Goldman-Rakic P.S., Roth R.H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Nat Acad Sci USA. 93:1996;1325-1329.
66. Narayanan S., Willin D., Dalia A., Wallace L., Uretsky N. Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav. 54:1996;565-573.
67. Nishijima K., Kashiwa A., Hashimoto A., Iwama H., Umino A., Nishikawa T. Differential effects of phencyclidine and methamphetamine on dopamine metabolism in rat frontal cortex and striatum as revealed by in vivo dialysis. Synapse. 22:1996;304-312.
68. Ouagazzal A., Nieoullon A., Amalric M. Locomotor activation induced by MK-801 in the rat Postsynaptic interactions with dopamine receptors in the ventral striatum . Eur J Pharmacol. 251:1994;229-236.
69. Pulvirenti L., Berrier R., Kreifeldt M., Koob G.F. Modulation of locomotor activity by NMDA receptors in the nucleus accumbens core and shell regions of the rat. Brain Res. 1994;231-236.
70. Ridley R.M., Haystead T.A., Baker H.F. An involvement of depamine in higher order choice mechanisms in the monkey. Psychopharmacol. 72:1981;173-177.
71. Riley B.P., Tahir E., Rajagopalan S., et al. A linkage study of the N-methyl-D-aspartate receptor subunit gene loci and schizophrenia in southern African Bantu-speaking families. Psychiatr Genet. 7:1997;57-74.
72. Rosenbaum G., Cohen B.D., Luby E.D., Gottlieb J.S., Yelen D. Comparison of Sernyl with other drugs. Arch Gen Psychiatry. 1:1959;651-656.
73. Rosse R.B., Fay-McCarthy M., Kendrick K., et al. D-Cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 19:1996;444-450.
74. Salamone J.D., Cousins M.S., Snyder B.J. Behavioral functions of nucleus accumbens dopamine Empirical and conceptual problems with the anhedonia hypothesis . Neurosci Biobehav Rev. 21:1997;341-359.
75. Sawaguchi T., Goldman-Rakic P.S. D1-dopamine receptors in prefrontal cortex Involvement in working memory . Science. 251:1991;947-949.
76. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task . J Neurophysiol. 71:1994;515-528.
77. Sayed Y., Garrison J.M. The dopamine hypothesis of schizophrenia and the antagonistic action of neuroleptic drugs - a review. Psychopharmacol Bull. 19:1983;283-288.
78. Simeon J., Fink M., Itil T.M., et al. D-cycloserine therapy of psychosis by symptom provocation. Compr Psychiat. 11:1970;80-88.
79. Smith K.E., Borden L.A., Hartig P.R., Branchek T., Weinshank R.L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron. 8:1992;927-935.
80. Steinpreis R.E., Salamone J.D. The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine A microdialysis and behavioral study . Brain Res. 612:1993;263-273.
81. Supplisson S., Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci. 17:1997;4580-4590.
82. Taber M.T., Das S., Fibiger H.C. Cortical regulation of subcortical dopamine release Mediation via the ventral ventral tegmental area . J Neurochem. 65:1995;1407-1410.
83. Tanii Y., Nishikawa T., Hashimoto A., Takahashi K. Stereoselective antagonism by enantiomers of alanine and serine of phencyclidine-induced hyperactivity, stereotypy and ataxia in the rat. J Pharmacol Exp Ther. 269:1994;1040-1048.
84. Thompson D.M., Moerschbaecher J.M. Phencyclidine in combination with d-amphetamine Differential effects on acquisition and performance of response chains in monkeys . Pharmacol Biochem Behav. 20:1984;619-627.
85. Thompson D.M., Winsauer P.J., Mastropaolo J. Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacol Biochem Behav. 26:1987;401-405.
86. Toth E., Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res. 11:1986;393-400.
87. Toth E., Weiss B., Banay-Schwartz M., Lajtha A. Effect of glycine derivatives on behavioral changes induced by 3-mercaptopropionic acid or phencyclidine in mice. Res Comm Psychol Psychiat Behav. 11:1986;1-9.
88. Tsai G., Passani L.A., Shusher B.S., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52:1995;829-836.
89. Verma A., Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats Modulation by dopamine . J Neurosci. 16:1996;373-379.
90. Wan F.-J., Swerdlow N.R. Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res. 722:1996;168-176.
91. Weight et al 1980 p. 3 Weight ML, Ridley RM, Baker HF (1980) The effect of amphetamine on delayed response performance in the monkey. Pharmacol Biochem Behav 12:861-864.
92. Williams S.M., Goldman-Rakic P.S. Blockade of dopamine D1 receptors enhances memory fields of prefrontal neurons in primate cerebral cortex. Nature. 376:1995;572-575.
93. Wood P.L. The co-agonist concept Is the NMDA-associated glycine receptor saturated in vivo? Life Sci. 57:1995;301-310.
94. Zafra F., Aragon C., Olivares L., Danbolt N.C., Gimenez C., Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells. J Neurosci. 15:1995;3952-3969.